Global TB Vaccines Market Growth 2025-2031
Description
The global TB Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. Today, the only effective tuberculosis vaccine in common use is bacilli Calmette-Guérin (BCG), first used in 1921.About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children, (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%.Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists because the disease has become increasingly drug-resistant.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “TB Vaccines Industry Forecast” looks at past sales and reviews total world TB Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected TB Vaccines sales for 2025 through 2031. With TB Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TB Vaccines industry.
This Insight Report provides a comprehensive analysis of the global TB Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TB Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TB Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TB Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TB Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of TB Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Immunotherapeutic Vaccines
Booster Vaccines
Others
Segmentation by Application:
Hospitals
Private Clinics
Research Institutes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck & Co.,Inc
Sanofi Pasteur
Japan BCG Laboratory
China National Biotec Group
Serum Institute
India Pvt. Ltd
InterVax Ltd
GreenSignal
Bio Pharma Limited
Statens Serum Institut
Key Questions Addressed in this Report
What is the 10-year outlook for the global TB Vaccines market?
What factors are driving TB Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do TB Vaccines market opportunities vary by end market size?
How does TB Vaccines break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. Today, the only effective tuberculosis vaccine in common use is bacilli Calmette-Guérin (BCG), first used in 1921.About three out of every 10,000 people who get the vaccine experience side effects, which are usually minor except in severely immuno-depressed individuals. While BCG immunization provides fairly effective protection for infants and young children, (including defence against TB meningitis and miliary TB), its efficacy in adults is variable, ranging from 0% to 80%.Several variables have been considered as responsible for the varying outcomes. Demand for TB immunotherapy advancement exists because the disease has become increasingly drug-resistant.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “TB Vaccines Industry Forecast” looks at past sales and reviews total world TB Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected TB Vaccines sales for 2025 through 2031. With TB Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TB Vaccines industry.
This Insight Report provides a comprehensive analysis of the global TB Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TB Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TB Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TB Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TB Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of TB Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Immunotherapeutic Vaccines
Booster Vaccines
Others
Segmentation by Application:
Hospitals
Private Clinics
Research Institutes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck & Co.,Inc
Sanofi Pasteur
Japan BCG Laboratory
China National Biotec Group
Serum Institute
India Pvt. Ltd
InterVax Ltd
GreenSignal
Bio Pharma Limited
Statens Serum Institut
Key Questions Addressed in this Report
What is the 10-year outlook for the global TB Vaccines market?
What factors are driving TB Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do TB Vaccines market opportunities vary by end market size?
How does TB Vaccines break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
87 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for TB Vaccines by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for TB Vaccines by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
